Tada wrote: "I am not a scientist but force myself to read most of this stuff.  Do I not have reason to hang on to some optimism still given that the conclusion speaks to pan-BET inhibitors and that apabetalone is a BD-specific BET inhibitor?"

FutTheWuk wrote: "It would seem the BD2 selectivity of APB makes it an exception the the findings in BDAZ article. Somebody prove me wrong."

The new study investigated the effects of both pan-inhibitor JQ1 and highly BD2-selective inhibitor ABBV-744 and found both to be deleterious in SARS-Cov2-infected mice. However, they did not test apabetalone so one cannot definitively conclude that apabetalone would have been harmful in this study too.

Tada wrote: "Didn't the study done by the University of Nebraska look directly at the effects of APB on the lungs of COVID mice and show that the cells were being repaired after administration of APB?"

As far as I remember, there has not been a published study assessing the effect of apabetalone on SARS-Cov2 (COVID-19) infection of mice (whole animal).....only cell culture and organoid studies. If you can point me in the direction of this study, I would be most appreciative.

BDAZ